Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR-UP: longitudinal evaluation of antifibrotic response to upadacitinib in Crohn's disease
2025-523038-16-00Phase 4Authorised
- Sponsor
- UZ Leuven
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of upadacitinib in Crohn's disease, sponsored by UZ Leuven. Planned start Oct 2026; status: authorised.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2025-523038-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523038-16-00.